Posted 1/28/2024, 9:30:00 AM
AI-Designed Drug for Inflammatory Bowel Disease Enters Human Testing
- Insilico Medicine has developed an AI-designed drug, ISM5411, to treat inflammatory bowel disease (IBD) which has entered Phase 1 clinical trials
- IBD impacts 1.6 million Americans, causing debilitating symptoms, and there is a need for new treatment options
- ISM5411 is designed to block the PHD protein to help rebuild the intestinal lining and promote long-term improvement
- Insilico used its AI platform, Chemistry42, to design the drug molecule based on biological and chemical data
- As AI-designed drugs enter clinics, educating the public on how they are developed and their potential benefits and risks is important